10-K/A

 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

 FORM 10-K/A

 (Amendment No.1)

 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended December 31, 2023
 OR

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM
 TO

 Commission File Number 001-36517

 Minerva Neurosciences, Inc.
 (Exact name of Registrant as specified in its Charter)

 Delaware

 26-0784194

 (State or other jurisdiction of
 incorporation or organization)

 (I.R.S. Employer
 Identification No.)

 1500 District Avenue
 Burlington, MA

 01803

 (Address of principal executive offices)

 (Zip Code)

 Registrant's telephone number, including area code: ( 617) 600-7373

 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class

 Trading
 Symbol(s)

 Name of each exchange
 on which registered

 Common Stock, $0.0001 par value per share

 NERV

 The Nasdaq Capital Market

 Securities registered pursuant to Section 12(g) of the Act: None
 Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES NO

 Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES NO

 Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES
 NO
 Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
 (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES
 NO
 Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated
 filer, a smaller reporting company, or an emerging growth company. See the definition of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2
 of the Exchange Act.

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

 Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2
 of the Exchange Act). YES NO
 The aggregate value of the Company's Common Stock held by non-affiliates
 of the Company was approximately $ 36.9 million as of June 30, 2023, when the last reported sales price was $9.14 per share.
 The number of shares of Registrant's Common Stock outstanding as of February 19, 2024 was 6,993,406.
 DOCUMENTS INCORPORATED BY REFERENCE
 Portions of the Registrant's Definitive Proxy Statement relating to the 2024 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A with the Securities and Exchange Commission are incorporated by reference into Part III of this Report. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant's fiscal year ended December 31, 2023.

 Auditor Firm PCAOB ID: 34

 Auditor Name: Deloitte & Touche, LLP

 Auditor Location: Boston, Massachusetts

 EXPLANATORY NOTE
 On February 22, 2024, Minerva Neurosciences, Inc. (the "Company") filed its Annual Report on Form 10-K
 for the fiscal year ended December 31, 2023 (the "Form 10-K").
 The sole purpose of this Amendment No. 1 is to correct a typographical error in Exhibit 23.1, Consent of Deloitte & Touche, LLP, independent registered public accounting firm (the "Consent"). The Consent has been amended to reference the correct date of the report of independent registered public accounting firm. The revised Exhibit 23.1 is filed as Exhibit 23.1 attached hereto.
 This Amendment speaks as of the filing date of the Form 10-K
 and does not reflect events occurring after the filing of the Form 10-K.
 No other revisions are being made to the Company's financial statements or any other disclosure contained in the Form 10-K.
 This Amendment is an exhibit-only filing. Except for Exhibit 23.1, this Amendment does not otherwise update any exhibits as originally filed or previously amended.
 In addition, as required by Rule 12b-15
 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), new certifications by the Company's principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a)
 or 15d-14(a)
 of the Exchange Act. As no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K,
 paragraphs 3, 4, and 5 of the certifications have been omitted. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.

 ITEM 15. Exhibits and Financial Statement Schedules
 (a)(3) Exhibits
 The following documents are filed as a part of this Form 10-K/A:

 Exhibit

 No.

 Description of Exhibit

 23.1

 Consent of Deloitte & Touche, LLP, independent registered public accounting firm

 31.1

 Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002

 31.2

 Certification of Chief Financial Officer (Principal Financial Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.LAB

 101.PRE

 SIGNATURES
 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 MINERVA NEUROSCIENCES, INC.

 By:

 /s/ Remy Luthringer, Ph. D.

 Remy Luthringer, Ph. D.
 Executive Chairman and

 Chief Executive Officer
 (Principal Executive Officer)

 Date: February 23, 2024